The read
- What changed. Compass closed down 27.3% on November 2, the day an unconfirmed trade report said Usona Institute had completed a new drug application for psilocybin in major depression. As of November 4, no Usona, FDA or SEC document confirms a filing, and Compass filed nothing that day.
- What matters. The programs differ in indication, design and documented evidence, and in application status. Compass has reported two Phase 3 Week 6 results and has a rolling NDA with final submission pending. Usona has reported no results and has no confirmed submission.
- What it does not answer. Whether Usona has filed, what its Phase 3 shows, what either label would say, and what either sponsor would charge.
- What would change the view. A Usona or FDA confirmation of the filing, uAspire results, Compass’s final submission, or a stated price or access plan.
The selloff and the filing speculation
Compass closed at $8.41 on Monday, November 2, down from $11.57 on October 30, on 16.9 million shares, about seven times its October average. Helus Pharma, whose HLP003 targets major depression, fell 16.9% the same day. Financial outlets attributed the fall to an unconfirmed trade-press report, citing unnamed sources, that Usona had completed an NDA. That report is speculation, not an established regulatory fact: Usona has not confirmed it, no FDA record shows it, and Compass made no SEC filing between October 28 and its November 3 quarterly report. Usona Institute declined to comment when contacted by Behavioral Wire about the reported NDA filing. The timing coincides with the report. It does not show that a filing exists, or that it alone caused the drop, and Helus’s fall suggests some repricing of the group.
On November 3 Compass said its own final NDA submission “will be filed in the next two weeks,” and shares closed at $8.59. On the same day’s earnings call, according to a transcript published by The Motley Fool, Compass CEO Kabir Nath said he wanted to “acknowledge that we are aware of the recent speculation regarding another potential filing. There has been no official statement, and we will not be providing any comments on this matter.” He did not name Usona, and the remark neither confirms nor denies a filing. BioSpace reported that Stifel kept its Buy rating and called the reported Usona filing “an overhang for a bit.” RBC saw “a buying opportunity” and “room for multiple competitors.”
Where each program stands
| Compass (COMP360, treatment-resistant depression) | Usona (psilocybin, major depression) | |
|---|---|---|
| Breakthrough designation | 2018 | 2019 |
| Priority voucher | Issued April 2026 | Issued April 2026 (per Compass’s 10-Q) |
| NDA status | Rolling review under way; Compass says final submission is pending, due within two weeks of Nov 3 | No confirmed submission; Usona’s 2025 impact report says it was “fully mobilizing toward” one |
| Phase 3 results public | Week 6 primary met in COMP005 and COMP006 | None |
| Approval | None | None |
Source: Compass Q3 10-Q and November 3 release; Usona impact report and psilocybin page; FDA’s priority voucher program page. The table lists only what company filings, FDA and Usona’s own materials establish. The reported Usona filing is not an established fact.
A voucher is a review mechanism for a specific application, not a timeline. FDA describes a “1-2 months target” and says the program “maintains the FDA’s established safety and effectiveness approval standards.” It does not show when an application is complete. Compass’s rolling submission, which lets FDA review an application in sections, is nearing completion by its own account; Usona’s is unconfirmed. Holding vouchers does not make the two timelines equivalent.
The three trials side by side
| uAspire (Usona) | COMP005 and COMP006 (Compass) | |
|---|---|---|
| Indication, population | Major depression, at least moderate; no treatment resistance required | Treatment-resistant depression: 2 to 4 failed treatments, MADRS 20 or higher |
| Dosing | One dose: 25 mg or 5 mg | COMP005: one 25 mg dose. COMP006: two doses 3 weeks apart (25, 10 or 1 mg) |
| Controls | Inactive placebo and a 5 mg arm | COMP005: placebo. COMP006: 1 mg and 10 mg arms, no placebo |
| Primary endpoint | MADRS, central rater, Day 43 | MADRS at Week 6: COMP005 vs placebo, COMP006 25 vs 1 mg |
| Follow-up | 1 year after Day 43 | Blinded to Week 26, open-label to Week 52 |
| Masking | Double-blind 6 weeks; what stays concealed afterward is unclear | Registry: four roles masked; blinded to Week 26 |
| Retreatment | Optional open-label 25 mg for any arm; criteria unpublished | COMP005 Part B: blinded repeat dose. COMP006 Part B: prespecified criteria, study drug or antidepressant. Part C: open-label 25 mg |
| Efficacy evidence | None public; no results posted | Week 6: COMP005 3.6 points vs placebo, COMP006 3.8 vs 1 mg. Week 26 curves, observed data only |
MADRS is the Montgomery-Asberg Depression Rating Scale, a clinician-rated symptom measure. Source: ClinicalTrials.gov records read November 4, 2026; Compass 8-K and presentation of July 7, September 9 release and Q3 10-Q; Usona statement of March 20, 2024. No record has posted results, a protocol or a statistical analysis plan.
What the designs can and cannot show
Compass’s two trials answer different questions. COMP005 tests whether one dose beats placebo. COMP006 tests a two-dose regimen at three strengths against low-dose controls. Compass describes it as designed to investigate whether a second dose can increase response, but every arm receives two doses and none receives one, so it cannot isolate the added effect of dose two. Both trials stay blinded to Week 26 with retreatment and antidepressants permitted, so that comparison describes a treatment strategy, not one dose, and Weeks 26 to 52 are open-label.
Usona put its questions into one trial, with a central-rater primary, a placebo arm and a 5 mg arm. A year of follow-up does not by itself make a year of controlled efficacy evidence. Participants from any arm who meet unpublished criteria can receive open-label 25 mg, so a controlled comparison after Day 43 would need prespecified follow-up outcomes, analysis by original assignment and stated rules for participants who cross to open-label treatment. The record does not say those exist. Usona’s statement of a “6-week randomized, double-blind treatment period” sits beside a registry line that full blinding “will be maintained until database lock at the conclusion of the trial.” Which governs follow-up is for Usona to say. No registry lists a durability outcome for either sponsor. This desk’s registry comparison sets out what each record measures after Week 6.
Commercial implications: documented and hypothetical
Documented: Usona is a 501(c)(3) nonprofit medical research organization. Its impact report says it is engaging payors, health systems and the VA and Department of Defense “to support responsible and affordable post-approval access.” It has published no price. Compass’s 10-Q lists the nonprofit model as a risk. Such organizations “may be willing to provide psilocybin-based products at cost or for free,” it says, which “could adversely affect the potential market for COMP360.” Compass has also published no price, and says it expects its launch in the first half of 2027.
Hypothetical: whether Usona prices below Compass, whether payers would cover one product differently from the other, and whether a nonprofit sponsor changes access in practice. The risk factor is Compass’s own concern, not a Usona commitment, and nonprofit status does not by itself set a price.
FDA’s July 2026 guidance: where the records differ
FDA’s final guidance on psychedelic drugs is nonbinding and names neither company. Compass’s trials began before the June 2023 draft and uAspire after it, and all three finished primary data collection before the final. Whether any protocol was amended is not public. The change between draft and final is covered here. On three points the guidance raises, the public records differ:
- Central raters blinded to allocation and visit. uAspire’s registry names a central-rater primary. For COMP005 and COMP006, whether central raters were used is not disclosed.
- A double-blind evaluation at 12 weeks. Neither program registers a Week 12 outcome, and none appears in the materials reviewed.
- Blinded long-term follow-up with prespecified retreatment criteria. Compass describes blinding to Week 26 with prespecified criteria. uAspire’s follow-up masking is unclear. Neither sponsor has published its criteria.
This describes public text. It is not a finding that either program meets the guidance, which addresses no specific trial.
Is Usona a near-term threat?
The evidence supports treating Usona as a credible competitor, with a Breakthrough designation, a priority voucher, a completed Phase 3 enrollment and a primary completion date of January 2026. It does not yet support treating it as a near-term one, for four reasons. The filing is unconfirmed. No uAspire data are public, while Compass’s Week 6 results are. The voucher is a review mechanism, not a timeline, and nothing public establishes how either review would run or what either label would say. And Usona’s pricing and access plan is undisclosed.
What may be easy to miss is how much separates the two on paper: an indication that does not require treatment resistance against one that does, a single dose against a two-dose design, and a nonprofit sponsor whose commercial posture is largely undocumented. Whether any of that matters depends on data and labels that do not yet exist. What the selloff reveals is how much of the picture rests on unpublished documents: a filing no one has confirmed, results Usona has not released, and prices neither sponsor has stated.